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BACKGROUND/PURPOSE: Parainfluenza viruses (PIVs) are common pathogens in respiratory tract 
infections. The aims of this study were to determine the clinical presentation of PIV infections 
in hospitalized children and to identify particular clinical indications that may effectively distinguish 
between different PIV serotypes.
METHODS: A retrospective review of data from children hospitalized with PIV infections at the Mackay 
Memory Hospital in Taipei between January 2005 and December 2007 was undertaken. Symptoms, signs, labo-
ratory findings and seasonal variations between different types of PIV (serotypes 1, 2 and 3) were compared.
RESULTS: A total of 206 patients [119 (57.8%) boys and 87 (42.2%) girls] were enrolled in the study. 
Seventy-four (35.9%) patients were infected with PIV serotype 1, 25 (12.1%) with serotype 2 and 107 (51.9%) 
with serotype 3. The most common clinical presentations were fever (81.1%), cough (66.0%), rhinorrhea 
(44.2%) and hoarseness (22.3%); 4.9% of the infected children also had skin rashes. No significant differences 
were found in average white blood cell counts and C-reactive protein levels between the three serotypes. PIV 
serotype 1 infections were discernible throughout the year; serotype 2 tended to cluster in the late summer 
and autumn of 2005 and 2007; and serotype 3 was more common in the spring and early summer.
CONCLUSION: The clinical presentation of PIV infection in hospitalized children ranges from upper 
respiratory tract infection to croup, bronchiolitis and viral bronchopneumonia, with the different types 
of PIV infections giving rise to similar symptoms. The seasonal distribution of the different serotypes is, 
nevertheless, quite distinct.
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Introduction
Parainfluenza virus (PIV) and respiratory syncytial virus 
(RSV) belong to the genus Paramyxoviridae. These PIVs are 
enveloped RNA viruses and commonly cause lower viral 
respiratory tract illnesses in children and high-risk popula-
tions.1,2 They are also a major cause of the hospitalization 
of children, with infants and younger children in particular 
being the major target for such infections.3–7 Four types 
of PIV infection have been identified since 1960.8,9 PIV-
related mortality and complications are typically reported 
in immunocompromised patients.1,4,8–11 Such infections 
may be asymptomatic in older children and adults, or 
they may even mimic a common cold. Reinfection by PIVs 
is common throughout the life because they often lack 
any durable immunity after a natural infection.1,6 The pri-
mary aims of this study were to determine the clinical 
manifestations of PIV infections in hospitalized children, 
and to uncover clues that might help to establish clinical 
distinctions between different PIV serotypes.
Methods
Patients and data collection
We reviewed the charts of pediatric patients from whom 
PIVs had been isolated as a result of throat cultures, and 
who were subsequently hospitalized at the Mackay 
Memorial Hospital in Taipei between January 2005 and 
December 2007. Cell lines, including Hep-2, MCDK, 
MRC-5 and A459 were used as the routine viral survey 
for respiratory tract infections. In those cases where a 
cytopathic effect was detected by microscopy, we used 
a specific monoclonal antibody from a commercially 
available respiratory viral panel1 (for herpes simplex virus, 
influenza A & B, parainfluenza 1–3 and adenovirus) and 
an identification kit (Light Diagnostic, Chemicon Inter-
national Inc, Temecula, USA) to identify the virus-infected 
cells. Three serotypes of PIV were identified. 
We recorded the clinical manifestations and diagnoses 
for each of the patients. Acute rhinitis, acute pharyngitis 
or tonsillitis were defined as the upper respiratory tract 
infection (URTI) group, while the lower respiratory tract 
infection (LRTI) group included patients with acute bron-
chiolitis, bronchopneumonia and pneumonia. Patients 
diagnosed with croup were allocated to a separate group. 
Respiratory tract symptoms or fever developing more 
than 7 days after hospitalization were defined as nosoco-
mial infections. Positive findings of a rotavirus antigen, 
mycoplasma serologic results or culture evidence suggest-
ing other pathogens were all regarded as co-infections.
The clinical information for the sample patients in this 
study was obtained either from initial post-hospitalization 
laboratory data or from data recorded at the time of the 
nosocomial infections. A C-reactive protein (CRP) level 
higher than 0.8 mg/dL was defined as an abnormal eleva-
tion. During the analysis of the laboratory data, all data 
on patients with co-infection or malignancy were ex-
cluded from the study. Analysis and comparison of clini-
cal presentations, laboratory data and seasonal variations 
in PIV infections for each of the three different serotypes 
were subsequently carried out.
Statistical analysis
The analysis of variance approach was used to examine the 
clinical presentations of the different PIV serotypes, with a 
comparison being undertaken between the categorical 
data using the χ2 test or Fisher’s exact test. A p value of 
< 0.05 was considered to be statistically significant.
Results
Patient distribution
The throat cultures of 218 pediatric patients yielded positive 
PIV samples during the study period. Following the exclu-
sion of all data pertaining to outpatients, 206 inpatients 
were enrolled in the study. Of these, 119 (57.8%) were boys 
and 87 (42.2%) were girls (male to female ratio = 1.37:1).
There were 74 (35.9%) cases of PIV serotype-1 infection 
(PIV-1), 25 (12.1%) cases of PIV serotype-2 infection (PIV-2), 
and 107 (51.9%) cases of PIV serotype-3 infection (PIV-3). 
Approximately two-thirds (134; 65.0%) of the children were 
under the age of 3 years while 57 (27.7%) were less than 
1 year old. Only 12 (5.8%) were over the age of 5 years.
The mean age of all PIV-infected children was 
25.0 ± 14.3 months. The mean age of the PIV-1-infected 
group was 28.5 ± 19.4 months, while that of the PIV-2-
infected group was 30.9 ± 18.8 months, and that of the PIV-
3-infected group was 21.7 ± 11.7 months. Those children 
with PIV-3 infections were significantly younger than 
those with PIV-1 infections ( p = 0.022). Furthermore, there 
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were no apparent cases of a child having a PIV re-infection, 
even with a different serotype. 
Clinical presentation
As shown in Table 1, the most common clinical presenta-
tions were fever (81.1%), cough (66.0%), rhinorrhea (44.2%), 
hoarseness (22.3%), tachypnea (18.9%) and wheezing (9.2%). 
Comparison of the clinical manifestations between the 
three PIV serotypes revealed that PIV-2 caused more fre-
quent episodes of wheezing than PIV-3 (p = 0.028). 
Cases presenting with hoarseness were also more fre-
quent in children with PIV-1 than in those with PIV-3 in-
fection (p = 0.026). The PIV-infected children examined in 
this study also presented with gastrointestinal tract symp-
toms, including vomiting (10.2%) or diarrhea (11.2%), but 
only a few patients had maculopapular skin rashes (4.9%). 
Most PIVs caused obvious respiratory tract infections 
and, indeed, only a very small proportion (11.6%) of chil-
dren presented with no respiratory symptoms (Table 2). 
Both URTI and LRTI were caused by different sero-
types of PIV and the ratios were quite similar. However, 
the proportion of croup cases was higher with PIV-1 
infection than with PIV-3 infection (p = 0.026) (Table 2). 
A total of 14 children (6.8%) were diagnosed with noso-
comial PIV infections; 13 (6.3%) had congenital anoma-
lies (including Down’s syndrome, Pierre-Robin syndrome 
and chromosome anomalies) and a further 14 (6.8%) 
were recorded as pre-term deliveries. Concomitant dis-
eases, such as gastroenteritis, acute otitis media, pyuria, 
urinary tract infection, sepsis or soft tissue infection 
were found in 84 (40.6%) of the children examined in this 
study.
Table 1. Clinical presentation of different serotypes of parainfluenza virus infectionsa
Clinical presentation Total (n = 206) PIV-1 (n = 74) PIV-2 (n = 25) PIV-3 (n = 107)
Fever 167 (81.1) 64 (86.5) 18 (72.0) 85 (79.4)
Cough 136 (66.0) 48 (64.9) 20 (80.0) 68 (63.6)
Rhinorrhea 91 (44.2) 29 (39.2) 13 (52.0) 49 (45.8)
Hoarsenessb 46 (22.3) 22 (29.7) 7 (28.0) 17 (15.9)
Tachypnea 39 (18.9) 15 (20.3) 5 (20.0) 19 (17.8)
Wheezingc 19 (9.2) 4 (5.4) 5 (20.0) 10 (9.3)
Nasal obstruction 9 (4.4) 3 (4.1) 2 (8.0) 4 (3.7)
Tonsil with exudate 6 (2.9) 3 (4.1) 1 (4.0) 2 (1.9)
Diarrhea 23 (11.2) 6 (8.2) 2 (8.0) 15 (14.0)
Vomiting 21 (10.2) 8 (10.8) 2 (8.0) 11 (10.3)
Skin rash 10 (4.9) 1 (1.4) 2 (8.0) 7 (6.5)
aData presented as n (%); bsignificantly more episodes of hoarseness were caused by PIV-1 infections than by PIV-3 infections (p = 0.026, χ2 
test); csignificantly more episodes of wheezing were caused by PIV-2 infections than by PIV-1 infections (p = 0.028, χ2 test). PIV = parainfluenza 
virus.
Table 2. Respiratory tract diseases in different types of parainfluenza virusa
Respiratory symptom Total (n = 206) PIV-1 (n = 74) PIV-2 (n = 25) PIV-3 (n = 107)
None 24 (11.6) 9 (12.2) 1 (4.0) 14 (13.1)
URTI 61 (29.6) 19 (25.6) 7 (28.0) 35 (32.7)
Croupb 45 (21.8) 22 (29.7) 6 (24.0) 17 (15.9)
LRTI 76 (36.9) 24 (32.4) 11 (44.0) 41 (38.9)
aData presented as n (%); bsignificantly more episodes of croup were caused by PIV-1 infections than by PIV-3 infections (p = 0.027, χ2 test). 
PIV = parainfluenza virus; URTI = upper respiratory tract infection; LRTI = lower respiratory tract infection.
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Our results also show that 30 of the children (14.6%) 
had culture- or serology-proven co-infections, such as RSV, 
rotavirus, enterovirus, adenovirus, methicillin-resistant 
Staphylococcus aureus, Escherichia coli, Salmonella, Enterobacter 
species and Mycoplasma pneumoniae. No statistical differences 
were discernible between the three types of PIV infections 
with regard to the duration of symptoms/signs prior to 
hospitalization (3.2 ± 2.6 days), the duration of fever (4.0 ± 
2.2 days) or the length of hospital stay (5.6 ± 2.9 days).
Laboratory results
Laboratory data on one acute leukemia patient with pan-
cytopenia and data on other patients who presented with 
co-infections were excluded from the total study sample 
of 206 patients. The hemoglobin levels of 175 of the sample 
patients ranged between 6.9–15.6 g/dL while the white 
blood cell counts ranged between 2.3–30.1 × 109/L, with a 
mean of 10.4 × 109/L.
The platelet count in 172 of the sample patients ranged 
between 137.0–731.0 × 109/L. CRP levels, which were available 
for only 160 patients, ranged between 0.02–19.9 mg/dL, 
with elevated CRP levels (> 0.8 g/dL) being evident in 39% 
of patients. No statistically significant differences were 
found in the laboratory results between patients with dif-
ferent PIV serotypes.
Seasonal variation
Evidence of PIV infections was found throughout the year 
during the study period (2005–2007), with PIV-1 infections 
commonly occurring throughout the entire period, and 
no seasonal peak being discernible. There were relatively 
fewer cases of PIV-2 infection, but there were two clear 
episodes of clustering in the summer/autumn of 2005 
and 2007. PIV-3 infections were the most common, with 
clustering being evident in northern Taiwan in the spring 
and early summer periods (Figure).
Discussion
PIV infections are generally associated with various upper 
and lower respiratory tract diseases, despite the fact that 
some of the children in this study presented no signs 
whatsoever of respiratory tract infection. Indeed, it has 
been reported that, of all PIV-infected infants or children, 
only 25% will generally develop clinically significant PIV 
diseases.3 Since most of the hospitalized children exam-
ined in this study (95%) were under 5 years of age, it may 
well be that younger children (with relatively immature 
immune systems) may present with much more severe ill-
nesses after becoming infected with PIV and would there-
fore have a greater demand for hospital care. Although 
cases of re-infection with PIV have been reported in the 
early stages of childhood,1,5 no such cases were evident in 
the present study.
Like RSV, PIV can cause respiratory symptoms/signs 
including fever, cough, massive nasal secretion, tachypnea 
and wheezing; however, compared with data on RSV, 
there are relatively few results relating to PIV-hospitalized 
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Figure. Number of patients with different serotypes of parainfluenza virus infections, 2005–2007. PIV = parainfluenza virus.
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children.1,12,13 According to previous studies, more severe 
respiratory illnesses are caused by PIV-3 than by serotypes 
1 and 2.1,5–6,8,11,12 However, in the present study, we found 
that the three PIV serotypes caused similar levels of URTI 
and LRTI. The reason for this may be that only hospital-
ized patients were enrolled in this study, so there may have 
been no significant differences in the severity of the 
illnesses.
Croup, one of the major reasons for hospitalization in 
infants and young children, is usually recognized as a typ-
ical clinical manifestation of PIV infections, particularly 
of type 1.3,4,12 However, PIV-2 was reported to have caused 
over 60% of all croup cases in one community in years 
during which PIV-1 was not endemic.1,9 Furthermore, a re-
lated study reported that PIV-1 accounted for all croup 
cases,4 whereas in the present study, we determined that 
51% of all croup cases were caused by PIV serotypes 2 or 3. 
Other viruses, in addition to PIV, may also cause croup 
in children. These include RSV, influenza A and B, adeno-
viruses, rhinoviruses and Mycoplasma.10 While influenza A 
infection is known to be more severe than PIV, it is never-
theless difficult to differentiate between the two based 
upon clinical symptoms alone.4 In this study, we did not 
simultaneously isolate the influenza virus from PIV-
infected children and, indeed, three children who had 
high fever and severe dyspnea were initially diagnosed 
with bacterial tracheitis.
PIV infections may also have extra-respiratory tract 
symptoms/signs. For example, 10% of the patients in the 
present study had gastrointestinal involvement, although 
skin rashes were less prevalent than in an earlier study.4 
PIV can cause many clinical diseases in adults, however, 
isolating viruses from the throats of adults is more diffi-
cult than from children, essentially because of the shorter 
incubation period and lower viral load shedding seen in 
adults.
PIVs, which have been isolated from immunocompro-
mised patients with LRTI, are also a common cause of 
fever and neutropenia in children with cancer.9 Viral load 
shedding has been shown to persist for a considerable 
length of time in immunocompromised patients (includ-
ing those receiving bone marrow transplants or immuno-
suppressive agents) as well as those with leukemia, 
immunodeficiency and chronic disease.1,9 Although severe 
morbidity and mortality rates relating to PIV infections 
are invariably associated with immunocompromised pa-
tients,14–16 no mortality or severe sequelae occurred in any 
of the patients in the present study, despite the fact that 
some had underlying diseases.
Marx et al reported that PIV serotypes 1 and 3 infec-
tions occurred with distinct seasonal patterns, with such 
patterns found to be interactive amongst all three PIV 
serotypes.17 While PIV-1 infections occur the whole year 
round, PIV-2 infections are relatively less regular and 
predictable, although clusters of the infection have been 
reported to have a biennial pattern.1,4,8 In this study, we 
also found clustering in the late summer to autumn peri-
ods of 2005 and 2007, but not 2006, while clusters of 
PIV-3 infections occurred mainly in the spring and early 
summer. Similar epidemiological findings are reported 
in other studies,6,18 although one study carried out in 
New York found that PIV infections tended to peak dur-
ing the autumn months.19 Finally, some respiratory tract 
viruses may interact with others. A report in Mexico 
showed that a PIV epidemic was also associated with RSV 
and influenza epidemics.20
This was a retrospective study and records may be 
incomplete, which may result in statistical bias. We per-
formed throat viral cultures only on hospitalized patients 
or outpatients with severe infections. If we are to gain a 
complete understanding of the exact epidemiology of PIV 
infections, surveillance of both inpatients and outpatients 
are necessary.
Nevertheless, our data reveal the conditions for PIV 
infection in hospitalized children. In children, it is quite 
difficult to differentiate between one type of PIV infection 
and another, whether by clinical symptoms or by labora-
tory results. Although our analysis does not reveal any dif-
ferences in the severity of the different PIV serotypes, it 
does reveal differences in their endemic seasons.
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